Page 681 - Read Online

Abe et al. J Cancer Metastasis Treat 2020;6:51 I http://dx.doi.org/10.20517/2394-4722.2020.117 Page 13 of 15

immune responses. Cancer Biol Ther 2019;20:1047-56.
33. Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther 2017;4:25-43.
34. Picci P. Osteosarcomas (OS). In: Picci P, Manfrini M, Donati DM, et al, editors. In diagnosis of musculoskeletal tumors and tumor-like
conditions. 2nd ed. Cham, Switzerland: Springer; 2020. pp. 185-212.
35. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev
2014;40:523-32.
36. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol
2015;33:3029-35.
37. Khanna C, Fan TM, Gorlick R, et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer
Res 2014;20:4200-9.
38. Fan TM, Roberts RD, Lizardo MM. Understanding and modeling metastasis biology to improve therapeutic strategies for combating
osteosarcoma progression. Front Oncol 2020;10:13.
39. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol 2014;16:15-23.
40. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer 2014;14:722-35.
41. Tang QL, Xie XB, Wang J, et al. Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl
Cancer Inst 2012;104:749-63.
42. Ge W, Jakobsson E. Systems biology understanding of the effects of lithium on cancer. Front Oncol 2019;9:296.
43. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB
activation. Nature 2000;406:86-90.
44. Medunjanin S, Schleithoff L, Fiegehenn C, Weinert S, Zuschratter W, Braun-Dullaeus RC. GSK-3β controls NF-kappaB activity via
IKKγ/NEMO. Sci Rep 2016;6:38553.
45. Nishimura H, Nakamura O, Yamagami Y, et al. GSK-3 inhibitor inhibits cell proliferation and induces apoptosis in human osteosarcoma
cells. Oncol Rep 2016;35:2348-54.
46. Shimozaki S, Yamamoto N, Domoto T, et al. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of
β-catenin. Oncotarget 2016;7:77038-51.
47. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/β-catenin pathway in conventional high-
grade osteosarcoma. J Pathol 2010;220:24-33.
48. Thomas DM. Wnts, bone and cancer. J Pathol 2010;220:1-4.
49. Danieau G, Morice S, Rédini F, Verrecchia F, Royer BB. New insights about the Wnt/β-catenin signaling pathway in primary bone tumors
and their microenvironment: a promising target to develop therapeutic strategies? Int J Mol Sci 2019;20:3751.
50. Zhao Z, Jia Q, Wu MS, et al. Degalactotigonin, a natural compound from Solanum nigrum L., inhibits growth and metastasis of
osteosarcoma through GSK3β inactivation-mediated repression of the Hedgehog/Gli1 pathway. Clin Cancer Res 2018;24:130-44.
51. Lu K, Wang X, Chen Y, et al. Identification of two potential glycogen synthase kinase 3β inhibitors for the treatment of osteosarcoma.
Acta Biochim Biophys Sin (Shanghai) 2018;50:456-64.
52. Skapek SX, Ferrari A, Gupta AA, et al. Rhabdomyosarcoma. Nat Rev Dis Primers 2019;5:1.
53. Kaseb H, Kuhn J, Babiker HM. Rhabdomyosarcoma. StatPearls [Internet] 2020.
54. Leiner J, Le Loarer F. The current landscape of rhabdomyosarcomas: an update. Virchows Arch 2020;476:97-108.
55. Kashi VP, Hatley ME, Galindo RL. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model
systems. Nat Rev Cancer 2015;15:426-39.
56. Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther 2019;4:16.
57. Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Recent advances and challenges in the treatment of
rhabdomyosarcoma. Cancers (Basel) 2020;12:1758.
58. Chen X, Stewart E, Shelat AA, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013;24:710-24.
59. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting
a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014;4:216-31.
60. Rengaswamy V, Zimmer D, Süss R, Rössler J. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for
alveolar rhabdomyosarcoma therapy. J Control Release 2016;235:319-27.
61. Bharathy N, Berlow NE, Wang E, et al. The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion
oncogene in rhabdomyosarcoma. Sci Signal 2018;11:eaau7632.
62. Zeng FY, Dong H, Cui J, Liu L, Chen T. Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human
alveolar rhabdomyosarcoma cells. Biochem Biophys Res Commun 2010;391:1049-55.
63. Ding S, Wu TY, Brinker A, et al. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A 2003;100:7632-7.
64. Chen EY, DeRan MT, Ignatius MS, et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress
growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 2014;111:5349-54.
65. Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report.
Cancer Med 2014;3:1404-15.
66. Vlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT. Age as an independent prognostic factor for survival of localised
synovial sarcoma patients. Br J Cancer 2015;113:1602-6.
67. Thway K, Fisher C. Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol 2014;18:369-80.
68. Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov